{"entity":{"id":"directorate-pharmaceutical-affairs-malta","kind":"institution","name":"Directorate for Pharmaceutical Affairs (Malta)","aka":["DPA","Direttorat għall-Affarijiet Farmaċewtiċi","Government Formulary List","Government Formulary List Advisory Committee","GFLAC"],"tldr":"The unit of Malta's Ministry for Health that assesses new medicines for the Government Formulary List, the list of medicines the public health service gives free. It also manages the list and handles requests for medicines outside it.","summary":"The PPRI Pharma Brief for Malta, written by the Directorate's own staff and describing 2021, says the Directorate for Pharmaceutical Affairs forms part of the Department for Policy in Health. It receives applications for new medicines from marketing authorisation holders or clinical consultants, and its health technology assessment unit prepares assessments and presents them to the Government Formulary List Advisory Committee, a technical committee that recommends inclusion and a maximum reference price. The Advisory Committee for Health Care Benefits then advises the Minister for Health on budget impact, sustainability and capacity, and the Minister gives the final endorsement. The Directorate's Formulary Management Unit manages the Hospital Formulary List and the Out-Patients Formulary List, and its Pharmaceutical Pricing Unit calculates maximum reference prices. Listed medicines are bought by the Central Procurement and Supplies Unit, mostly by tender, and are free to entitled patients with no copayment. The brief says the initiative of setting aside budgeted funds for a disease area started as an oncology fund. The OECD and European Commission's 2025 Country Cancer Profile reports that none of a sample of new breast and lung cancer medicines with the highest clinical benefit was on the list, although all were available on a named-patient basis. The Directorate's own site refused a script, so OnCo has not read it.","asOf":"2026-11-16","links":[{"label":"PPRI Pharma Brief: Malta 2021, by the Directorate for Pharmaceutical Affairs (PDF, published June 2022)","url":"https://ppri.goeg.at/system/files/inline-files/PPRI_Pharma_Malta_Brief_final.pdf"},{"label":"OECD and European Commission: EU Country Cancer Profile Malta 2025, sections 5.1 and 5.3 (PDF)","url":"https://cancer-inequalities.jrc.ec.europa.eu/sites/default/files/docs/ccp2025/ec-oecd-mt-2024-1677-en.pdf"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["malta-medicines-authority","sir-anthony-mamo-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guardamangia","country":"MT","lat":35.892,"lng":14.493,"institutionType":"government","website":"https://pharmaceuticalaffairs.gov.mt","programs":["Health technology assessment for the Government Formulary List","Formulary Management Unit","Pharmaceutical Pricing Unit","Exceptional medicinal treatment requests"]},"route":"/institutions/directorate-pharmaceutical-affairs-malta/","neighbours":{"institution":[{"id":"malta-medicines-authority","kind":"institution","name":"Malta Medicines Authority","route":"/institutions/malta-medicines-authority/"},{"id":"sir-anthony-mamo-oncology-centre","kind":"institution","name":"Sir Anthony Mamo Oncology Centre","route":"/institutions/sir-anthony-mamo-oncology-centre/"}]}}